Cohort profile: COBLAnCE: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of life

• Published in: BMJ open Vol. 13; no. 12; p. e075942
• Main Authors: Lebret, Thierry, Bonastre, Julia, Fraslin, Aldéric, Neuzillet, Yann, Droupy, Stéphane, Rebillard, Xavier, Vordos, Dimitri, Guy, Laurent, Villers, Arnauld, Schneider, Marc, Coloby, Patrick, Lacoste, Jean, Méjean, Arnaud, Lacoste, Jacques, Descotes, Jean-Luc, Eschwege, Pascal, Loison, Guillaume, Blanché, Hélène, Mariani, Odette, Ghaleh, Bijan, Mangin, Anthony, Sirab, Nanor, Groussard, Karine, Radvanyi, François, Allory, Yves, Benhamou, Simone
• Format: Journal Article
• Language: English
• Published: England British Medical Journal Publishing Group 20.12.2023; BMJ Publishing Group LTD; BMJ Publishing Group
• Series: Cohort profile
• Subjects: Biomarkers; Bladder cancer; Cancer; Chronic illnesses; Cystectomy; Disease; Epidemiology; Female; Humans; Life Sciences; Lifestyles; Male; Medical prognosis; Non-Muscle Invasive Bladder Neoplasms; Patients; Prognosis; Prospective Studies; Quality of Life; Recruitment; Smoking; Tobacco; Urinary Bladder Neoplasms - pathology; Urine; Urological surgery; Urological tumours; United States > US; Urological tumours; EPIDEMIOLOGY; Prognosis
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2023-075942

PurposeBladder cancer is a complex disease with a wide range of outcomes. Clinicopathological factors only partially explain the variability between patients in prognosis and treatment response. There is a need for large cohorts collecting extensive data and biological samples to: (1) investigate gene-environment interactions, pathological/molecular classification and biomarker discovery; and (2) describe treatment patterns, outcomes, resource use and quality of life in a real-world setting.ParticipantsCOBLAnCE (COhort to study BLAdder CancEr) is a French national prospective cohort of patients with bladder cancer recruited between 2012 and 2018 and followed for 6 years. Data on patient and tumour characteristics, treatments, outcomes and biological samples are collected at enrolment and during the follow-up.Findings to dateWe describe the cohort at enrolment according to baseline surgery and tumour type. In total, 1800 patients were included: 1114 patients with non-muscle-invasive bladder cancer (NMIBC) and 76 patients with muscle-invasive bladder cancer (MIBC) had transurethral resection of a bladder tumour without cystectomy, and 610 patients with NMIBC or MIBC underwent cystectomy. Most patients had a solitary lesion (56.3%) without basement membrane invasion (71.7% of Ta and/or Tis). Half of the patients with cystectomy were stage ≤T2 and 60% had non-continent diversion. Surgery included local (n=298) or super-extended lymph node dissections (n=11) and prostate removal (n=492). Among women, 16.5% underwent cystectomy and 81.4% anterior pelvectomy.Future plansCOBLAnCE will be used for long-term studies of bladder cancer with focus on clinicopathological factors and molecular markers. It will lead to a much-needed improvement in the understanding of the disease. The cohort provides valuable real-world data, enabling researchers to study various research questions, assess routine medical practices and guide medical decision-making.